Immunotherapy and radiation with or without chemotherapy for high-risk soft tissue sarcoma
Treatments studied
Part of Cancer clinical trials.
This trial tests whether adding chemotherapy before surgery to a combination of immunotherapy (pembrolizumab) and radiation therapy improves outcomes for people with high-risk soft tissue sarcoma (UPS or LPS) in the arm or trunk. It aims to see if this approach can shrink tumors and reduce the chance of cancer returning.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a type of soft tissue sarcoma called UPS or LPS in your arm, leg, or trunk wall.
- Your tumor is at least 5 cm (about 2 inches) and is considered high grade (grade 3).
- You are healthy enough for surgery and radiation therapy, and your heart, liver, and kidney function are within acceptable limits.
- You have not had prior chemotherapy, radiation, or surgery (other than a biopsy) for this cancer.
- You do not have cancer that has spread to other parts of the body, and you do not have certain active infections or autoimmune conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of radiation therapy, a lower dose of chemotherapy, and an immunotherapy drug called toripalimab before surgery for a rare type of soft tissue sarcoma called undifferentiated pleomorphic sarcoma (UPS). The aim is to shrink the tumor and improve the chances of successful surgery.
This trial compares a combination of immunotherapy (pembrolizumab) plus chemotherapy (doxorubicin) versus chemotherapy alone for people with aggressive, poorly differentiated sarcomas that have spread or cannot be removed. The goal is to see if adding immunotherapy helps shrink tumors or slow their growth better than chemotherapy alone.
This study tests whether giving radiation, chemotherapy, and immunotherapy together can control high-risk soft tissue sarcoma that is hard to remove or may come back after surgery. It may help by attacking cancer in different ways, including boosting the immune system.
This trial tests a combination of immunotherapy (atezolizumab), chemotherapy (doxorubicin), and radiation before and after surgery for people with high-risk soft tissue sarcoma in the arm, leg, or trunk. The goal is to see if this approach can improve outcomes.
This trial tests a precision medicine approach by giving targeted therapy before surgery for high-risk soft tissue sarcoma. The goal is to see if matching treatment to your tumor's type can improve outcomes.
This Phase 1/2 trial tests whether combining radiation with two targeted/immune medicines can shrink or control high-risk soft tissue sarcoma and improve outcomes. It may help patients whose tumors are large, hard to fully remove, or have come back after prior treatment.
Hear when a new Resectable Liposarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.